Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network

2020

Haematologica , Volume Online ahe

Additional Metadata
Persistent URL	doi.org/10.3324/haematol.2020.267831, hdl.handle.net/1765/133788
Journal	Haematologica
Organisation	Department of Immunology
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Bruinink, D.H.O., Oliva, S, Rihova, L., Schmitz, A, Gilestro, M., te Marvelde, J.G, … van der Velden, V.H.J. (2020). Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network. Haematologica, Online ahe. doi:10.3324/haematol.2020.267831

Publication